Get the Stockscreener App
1.67
11.17%
-0.21
After Hours:
1.72
0.05
+2.99%
Ernexa Therapeutics Inc stock is traded at $1.67, with a volume of 443.41K.
It is down -11.17% in the last 24 hours and up +39.75% over the past month.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
See More
Previous Close:
$1.88
Open:
$1.88
24h Volume:
443.41K
Relative Volume:
0.13
Market Cap:
$12.81M
Revenue:
$598.00K
Net Income/Loss:
$-44.93M
P/E Ratio:
-0.201
EPS:
-8.31
Net Cash Flow:
$-17.32M
1W Performance:
+40.34%
1M Performance:
+39.75%
6M Performance:
-45.02%
1Y Performance:
-89.29%
1-Day Range:
$1.63
$1.89
1-Week Range:
$1.20
$2.8599
52-Week Range:
$1.09
$18.00
Ernexa Therapeutics Inc Stock (ERNA) Company Profile
Name
Ernexa Therapeutics Inc
Sector
Industry
Phone
(617) 798-6700
Address
1035 CAMBRIDGE STREET, CAMBRIDGE
Compare ERNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERNA
Ernexa Therapeutics Inc
|
1.67 | 14.42M | 598.00K | -44.93M | -17.32M | -8.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ernexa Therapeutics Inc Stock (ERNA) Latest News
Will breakout in Ernexa Therapeutics Inc. lead to full recoveryProduct Launch & Reliable Entry Point Alerts - newser.com
Why Ernexa Therapeutics Inc. stock is recommended by analystsLayoff News & Scalable Portfolio Growth Methods - newser.com
Is it too late to sell Ernexa Therapeutics Inc.Weekly Gains Report & Expert Approved Trade Ideas - newser.com
Multi asset correlation models including Ernexa Therapeutics Inc.Analyst Downgrade & Consistent Return Strategy Ideas - newser.com
How strong is Ernexa Therapeutics Inc. stock revenue growthJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - newser.com
Will Ernexa Therapeutics Inc. bounce back from current supportGap Up & Real-Time Buy Signal Alerts - newser.com
How Ernexa Therapeutics Inc. stock reacts to oil pricesJuly 2025 Outlook & Long Hold Capital Preservation Plans - newser.com
Risk vs reward if holding onto Ernexa Therapeutics Inc.July 2025 Rallies & Free Safe Entry Trade Signal Reports - newser.com
Sector ETF performance correlation with Ernexa Therapeutics Inc.Trade Entry Summary & Precise Buy Zone Identification - newser.com
Should I hold or sell Ernexa Therapeutics Inc. stock in 2025July 2025 Levels & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into Ernexa Therapeutics Inc.Weekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
Analyzing drawdowns of Ernexa Therapeutics Inc. with statistical toolsEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Is Ernexa Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
How to monitor Ernexa Therapeutics Inc. with trend dashboards2025 Year in Review & Stock Portfolio Risk Control - newser.com
Will Ernexa Therapeutics Inc. stock benefit from automationTrade Analysis Report & Fast Gain Stock Trading Tips - newser.com
Is Ernexa Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
3 Penny Stocks to Watch Now, 10/30/25 - TipRanks
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last? - ts2.tech
ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials - Asianet Newsable
Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer - PR Newswire
/C O R R E C T I O N -- Cellipont Bioservices/ - Lelezard
Ernexa Therapeutics Soars: Innovation’s Role Debated - StocksToTrade
Ernexa Therapeutics stock soars after Cellipont manufacturing deal By Investing.com - Investing.com Philippines
Ernexa Therapeutics stock soars after Cellipont manufacturing deal - Investing.com
Cellipont Bioservices and Ernexa Therapeutics enter cell therapy manufacturing partnership to advance ERNA-101 toward clinical trials in ovarian cancer - MarketScreener
ERNA Stock Price and Chart — NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc Stock (ERNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):